Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > LATEST
LATEST
-
REGULATORY CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
-
BUSINESS M3’s MR-kun Hit by Data Breach, Pharma Staff and Doctors Exposed
October 16, 2026
-
BUSINESS Santen Hits 93% Weekly AI Adoption in R&D, Digitizes Truckload of Research Records
October 16, 2026
-
REGULATORY Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
-
ORGANIZATION Japan Generics Society Calls for Risk-Based Nitrosamine Controls
October 16, 2026
-
BUSINESS Medley Reports Cyberattack, Patient Data at Risk at Up to 787 Facilities
October 16, 2026
-
BUSINESS Takeda’s TAK-881 Shaves 56 Minutes Off Infusion Time vs HyQvia
October 16, 2026
-
ORGANIZATION Japan Expert Calls for Earlier Access to Anti-Obesity Drugs
October 16, 2026
-
BUSINESS UCB Japan Recalls Cimzia Over Needle Retraction Defect
October 16, 2026
-
BUSINESS AstraZeneca Releases Breztri 14.4 for Asthma in Japan
October 16, 2026
-
ORGANIZATION Japan Falling Behind US, China in Pharma Innovation, EFPIA Chief Urges Action
October 15, 2026
-
BUSINESS Takeda’s Narcolepsy Med Orzeyful Now Available in Japan, China
October 15, 2026
-
REGULATORY Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
-
BUSINESS JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
-
BUSINESS Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
-
BUSINESS Rhythm’s Imcivree Debuts in Japan for Acquired Hypothalamic Obesity
October 15, 2026
-
REGULATORY Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
-
BUSINESS Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
-
BUSINESS Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
-
REGULATORY Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…